NCT02238860

A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis

A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Asian Institute Of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV Decompensated Cirrhosis. The investigators aimed to compare safety/efficacy and virological response in patients with HBV Decompensated Cirrhosis.

Detailed description

The effectiveness of entacavir and tenofovir has not been prospectively studied in HBV Decompensated cirrhosis? This prospective, randomised clinical trial will help us in better patient management more efficacy and cost effectiveness.

Conditions

• Cirrhosis Due to Hepatitis B

Interventions

Type	Name	Description
DRUG	Entacavir	Entacavir-0.5 mg ,OD,for
DRUG	Tenofovir	Tenofovir ,300 mg,OD,for 48 weeks

Timeline

• Start date: 2014-09-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2014-09-12
• Last updated: 2014-09-12

Locations

1 site across 1 country: Pakistan